Anti-obesity drugs: To be or not to be?

Obesity Reviews

Volumn 11, Issue 12, 2010, Pages 833-834

  Dvorak, R V ^a   Sharma, A M ^b   Astrup, A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; LORCASERIN; LORQESS; PHENTERMINE; QNEXA; SIBUTRAMINE; TOPIRAMATE; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; DRUG APPROVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMED CONSENT; OBESITY; OFF LABEL DRUG USE; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CONSUMER PRODUCT SAFETY; DRUG APPROVAL; HUMANS; OBESITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78649452369     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2010.00828.x     Document Type: Editorial

References (1)

1. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggion AO, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, for the SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.